N/A N=135 Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.
Atrial Fibrillation
Primary: Procedure Duration — 159.2; 170.7 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention
Urinary Retention · Underactive Bladder
Primary: Number of Participants With Evoked Bladder Contractions of at Least 20 Centimeters of Water (cmH2O) During the Stage-4 Test — 0 Participants
N/A N=30 Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
Coronary Microvascular Dysfunction
Primary: Change in Coronary Flow Reserve (CFR) — 3.04 ratio — p=0.0137
N/A N=204 Impact of Online Ordering on Low-Income Adults' Food Security in Online Food Pantry Settings
Food Security
Primary: U.S. Household Food Security Survey Module: Six-Item Short Form Score — 3.6; 2.7 score on a scale
Phase 2 N=322 A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Primary: Stage A: Percentage of Participants With Confirmed Evidence of Clinical Improvement(ECI) — 66.5 percentage of participants
Phase 3 N=152 Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer
Primary: Number of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs) — 91 Participants
Phase 2 N=293 COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers
Healthy · Chronic Stable Illness
Primary: 50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987…
N/A N=27 UFPTI 2105-BR05: Improving Breast Radiotherapy Setup and Delivery Using Mixed-Reality Visualization
Breast Cancer
Primary: Number of Computed Tomography (CBCTs) a Participant Receives During Radiation Therapy Treatment as Quantified Via Counting the Number Used During the Setup Process. — 2…
Phase 3 N=438 Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace
Tobacco Smoking · Nicotine Dependence
Primary: Cigarettes Per Day (CPD) — 7.05; 12.95 cigarettes per day
N/A N=34 Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes
Tobacco Dependence
Primary: Change in Blood Oxygen Level Dependent (BOLD) Signal Collected by Functional Magnetic Resonance Imaging (fMRI) During Monetary Delay Discounting Task — 0.13; -0.16…
Phase 1 N=16 A Study of LY3316531 in Healthy Participants
Healthy
Primary: Change From Baseline in Capsaicin-Induced Dermal Blood Flow Following LY3316531 Compared to Placebo — 327.19; 63.65 milliliter/100gram/minute (mL/100g/min) — p=<0.001
Phase 1 N=18 Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects
Healthy
Primary: Part 1: AUC0-tz of BI 409306 — 603; 643 nanomol (nmol)*hour (h)/Litre (L)
Phase 2 N=36 Administration of Kisspeptin in Patients With Hyperprolactinemia
Hyperprolactinemia · Hypogonadism
Primary: Average Change in Number of Luteinizing Hormone (LH) Pulses Over 10 Hours — 3.000 pulses per 10 hour period
N/A N=181 PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
Diabetes Mellitus · Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Effectiveness Measure - Mean Absolute Relative Difference (MARD) for Paired CGM and Reference Glucose Measurements — 9.1; 8.5 percent
Phase 3 N=554 Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 58.06; NA Months